Announcement on Voluntary Disclosure of Obtaining Report on Ethical Approval for Key Phase III Clinical Trials of 3rd-generation ALK Kinase Inhibitor SY-3505

About this update from Shouyao Holdings Beijing Co. Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining Report on Ethical Approval for Key Phase III Clinical Trials of 3rd-generation ALK Kinase Inhibitor SY-3505The abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference:" target="_blank">View Attachment

View stock analysis, news, and events for Shouyao Holdings Beijing Co. Ltd. Class A